ライフサイエンスコーパス: eGFR

1 eGFR and CFR were associated with diastolic and systolic

2 eGFR is now recommended by clinical practice guidelines,

3 eGFR was reassessed after 4 years in 124 available diabe

4 x was 24.7 kg/m(2) [IQR, 21.9-28.4 kg/m(2)], eGFR was 105 mL/min/1.73 m(2) [IQR, 95.7-113.0 mL], 9.7%

5 to <60 mL/minute/1.73 m2 (n = 144) or >=25% eGFR drop to <90 mL/minute/1.73 m2 (n = 599), and 322 co

6 ome); (2) total HF hospitalizations; and (3) eGFR slope.

7 nts aged 18 or older with CKD stage 3b or 4 (eGFR 15-45 ml/min per 1.73 m(2)).

8 e and sex with metformin prescription across eGFR level before and after the FDA label change.

9 peptides as the base model to which we added eGFR and urine albumin-to-creatinine ratio.

10 After adjustment, eGFR declined significantly faster in patients with sick

11 to 84.2% after adjustment for baseline age, eGFR, BMI, sex, and race.

12 in-to-creatinine ratio of 300 to 5000 and an eGFR of 25 to less than 75 ml per minute per 1.73 m(2).

13 ; 63% female; 22% black) studied, 35% had an eGFR <60 mL.min(-1).1.73 m(-2), a median left ventricula

14 Overall, 1664 (47.3%) had an eGFR <90 mL/min and 1087 (30.9%) an UPCR >=15 mg/mmol.

15 I eGFR was 97 mL/min/1.73 m2, and 38% had an eGFR <90 mL/min/1.73 m2.

16 in milligrams and creatinine in grams) or an eGFR decrease of at least 3.0 ml per minute per 1.73 m(2

17 We conclude that an eGFR is sufficient for assessing kidney function in pati

18 The metformin label change to an eGFR-based contraindication may have reduced racial and

19 Cohort Study which enrolled children with an eGFR of 30-90 ml/min per 1.73 m(2) and then assessed eGF

20 f cycles with uCrCl < 50 ml/min/1.73m(2) and eGFR >= 50 ml/min/1.73m(2) (i.e. a "false negative" resu

21 tics UPPod:CR predicted both albuminuria and eGFR loss.

22 med the dominance of molecular AKI, CKD, and eGFR.

23 Avg (CrCl and eGFR) also offered modestly improved accuracy compared w

24 asured GFR is unavailable, the Avg (CrCl and eGFR) provides a better estimate of kidney function in k

25 mated iGFR, and their average [Avg (CrCl and eGFR)] essentially eliminated the GFR bias (median bias

26 and higher PTH, HOMA-IR, HOMA-B, hs-CRP, and eGFR than white women (all P values < 0.0001).

27 hite primary care patients with diabetes and eGFR>=30 ml/min per 1.73 m(2) in a large health system (

28 research to improve the accuracy of mGFR and eGFR.

29 s an inverse linear relation between PTH and eGFR in white women after accounting for 25(OH)D, PTH an

30 Overall agreement between uCrCl and eGFR was low, with qualitative analysis suggesting frequ

31 ls to estimate slopes with up to four annual eGFR assessments, and Cox proportional hazards models to

32 Incident CKD was defined as eGFR <60 ml/min per 1.73 m(2) with eGFR decline >=1 ml/m

33 defined incident CKD (stage 3 or higher) as eGFR<60 ml/min per 1.73 m(2) and >=25% decline from base

34 ciated with clinical renal endpoints such as eGFR or proteinuria, there was a consistent pattern of i

35 smin (ogen) uria and edema status as well as eGFR.

36 30-90 ml/min per 1.73 m(2) and then assessed eGFR annually.

37 eeded to develop best practices to attenuate eGFR decline in such patients.

38 ars after transplantation, although baseline eGFR 1 month after transplantation was lower in the inte

39 Male sex, diabetes mellitus, and baseline eGFR >=90 ml/min per 1.73 m(2) were associated with fast

40 was no interaction between race and baseline eGFR on odds for incident AKI (P value for interaction =

41 d race (Black, White, or other) and baseline eGFR with AKI incidence among patients who underwent PCI

42 iabetes, treatment with an ARNI and baseline eGFR, but suggested treatment-by-subgroup interactions f

43 no significant association between baseline eGFR <60 ml/min per 1.73 m(2) and risk for dementia or M

44 Upon adjustment for baseline eGFR, this association became attenuated, suggesting tha

45 , type 2 diabetes, body mass index, baseline eGFR, and albuminuria.

46 Low baseline eGFR was associated with graded, higher odds of AKI inci

47 , higher glycated hemoglobin, lower baseline eGFR, and higher baseline urine albumin/creatinine ratio

48 Lower baseline eGFR, proton pump inhibitor use, and combination immune

49 ighest risk of ESRD with the lowest baseline eGFR group, there was a substantial increase in eGFR see

50 luated (median age 11 years; median baseline eGFR of 53 ml/min per 1.73 m(2)), 195 (30%) had a glomer

51 12,761 eligible individuals (median baseline eGFR, 103 ml/min/1.73 m2), 1,192 (9%) developed a CKD af

52 eplacing TDF by TAF, independent of baseline eGFR.

53 mean age, 64 years; postnephrectomy baseline eGFR, 48 ml/min per 1.73 m(2)), 117 progressive CKD even

54 int did not differ according to the baseline eGFR (<60 versus >=60 mL.min(-1).1.73 m(-2) (P-interacti

55 The baseline eGFR was 69.38 +/- 16.29 ml/min/1.73 m(2).

56 nued use of TDF in individuals with baseline eGFR <60 mL/min.

57 ersus 39.8 years; p < 0.0001) and had better eGFR (mean +/- SD 87.4 +/- 23.9 versus 80.1 +/- 20.7 mL/

58 end, placebo-treated CD subjects had better eGFR than projected by a prediction equation (mean diffe

59 To investigate the association between eGFR slopes and risks of death or cardiovascular events,

60 The associations between eGFR, cardiac mechanics, and cardiovascular events were

61 Both eGFR and mGFR are associated with error compared with tr

62 observed risks in participant categories by eGFR level.

63 type in general and in patients with CKD by eGFR and presence of comorbidities.

64 al, dialysis, and total health care costs by eGFR (Kidney Disease Improving Global Outcomes-defined e

65 dults, declining kidney function measured by eGFR is associated with increased risk for probable deme

66 ssociated with a lower creatinine/cystatin C eGFR at 2 years post-HCT.

67 We confirmed CKD (eGFR<60 ml/min per 1.73 m(2)) in 53 of 1227 (4.3%) evalu

68 min per 1.73 m(2)), 24 with nondialysis CKD (eGFR <60 ml/min per 1.73 m(2)), and 20 with ESKD treated

69 We included 743 cases with confirmed eGFR drop to <60 mL/minute/1.73 m2 (n = 144) or >=25% eG

70 In contrast, eGFR decreased by 5.8 mL/min (95% CI, 2.3-9.3) with cont

71 /minute/1.73 m2 (n = 599), and 322 controls (eGFR drop <15%).

72 combination of added kidney measures (creat-eGFR, cysC-eGFR, and urine albumin-to-creatinine ratio)

73 CysC-eGFR but not sCr-eGFR predicted the primary end point: o

74 we aimed to (1) longitudinally compare CysC-eGFR and sCr-eGFR, (2) assess their predictive value for

75 n of added kidney measures (creat-eGFR, cysC-eGFR, and urine albumin-to-creatinine ratio) led to sign

76 Addition of cysC-eGFR made the largest contribution to reclassification i

77 timal pair of added kidney measures was cysC-eGFR and urine albumin-to-creatinine ratio (DeltaC=0.019

78 LVAD and subsequently declined, whereas CysC-eGFR remained stable.

79 9-year-old individuals with mildly decreased eGFR (60-89 mL/min/1.73 m2), the model projected a furth

80 with CVD, and 74% with only mildly decreased eGFR of 60-89 mL/min/1.73 m2 at entry).

81 ey Disease Improving Global Outcomes-defined eGFR categories), adjusted for age, sex, and nonwhite ra

82 false negative" result when only determining eGFR).

83 AAV (MPA and GPA) and severe kidney disease (eGFR <30 ml/min per 1.73 m(2)).

84 reased the risk of >= 40% decline in CKD-EPI eGFR (HR 1.5, p = 0.001) and doubling of serum creatinin

85 tment for clinical variables, annual CKD-EPI eGFR decreased by - 0.56 mL/min/BSA/year for each logari

86 Mean CKD-EPI eGFR was 42 mL/min/BSA and median [IQR] uACR was 3 [11]

87 The median CKD-EPI eGFR was 97 mL/min/1.73 m2, and 38% had an eGFR <90 mL/m

88 ine Clearance (uCrCl) versus GFR estimation (eGFR) by the CKD-EPI formula versus both] is unclear.

89 in per 1.73 m(2) were associated with faster eGFR decline for both phenotypes.

90 trait and disease are associated with faster eGFR decline in black patients, with faster decline in s

91 Low hemoglobin S was associated with faster eGFR decline in sickle cell trait but may be confounded

92 ted hemoglobin A were associated with faster eGFR decline, but elevated hemoglobins F and A(2) were r

93 eir listing estimated glomerular filtration (eGFR) as well as based on their eGFR at the time of tran

94 ; P=7.8E-6 for urate) and mice (P=0.0003 for eGFR; P=0.0002 for urate) and confirmed as the primary c

95 tubule was enriched in humans (P=8.5E-5 for eGFR; P=7.8E-6 for urate) and mice (P=0.0003 for eGFR; P

96 .2E-5 for urate) and liver (P=6.8.10(-5) for eGFR).

97 S loci were enriched in kidney (P=9.1E-8 for eGFR; P=1.2E-5 for urate) and liver (P=6.8.10(-5) for eG

98 CKD progression and mortality, adjusting for eGFR, albuminuria, and other confounding characteristics

99 For FGF23, further adjustment for eGFR had similar results.

100 ease and heart failure) after adjustment for eGFR.

101 edictions for developing CKD stage 3 and for eGFR trajectory.

102 cipants at all CKD stages when corrected for eGFR and age, but not when adjusted for serum phosphate.

103 en consortium provided GWAS summary data for eGFR, urinary albumin-creatinine ratio (UACR), BUN, and

104 he tertile with both normal kidney function (eGFR 84 +/- 11.7 ml/min/1.73m(2)) and norm-albuminuria a

105 howed higher correlation with estimated GFR (eGFR) than UAER (r = - 0.23).

106 ted I-iothalamate GFR (iGFR), estimated GFR (eGFR), underestimated iGFR, and their average [Avg (CrCl

107 s have seen major advances in estimated GFR (eGFR).

108 we concentrated on clinical (estimated GFR [eGFR], proteinuria, time posttransplant, donor-specific

109 were independently associated with a higher eGFR during follow-up.

110 r glomerular area was associated with higher eGFR (p-value<=0.001) and increased graft survival after

111 with a mean loss of 10 mL/min in the highest eGFR group.

112 undergoing TAVR, even with baseline impaired eGFR, CKD stage is more likely to stay the same or impro

113 Switching from TDF to TAF improves eGFR and proteinuria in patients with renal dysfunction.

114 The change in eGFR did not differ significantly between the allopurino

115 valuate the difference in the mean change in eGFR per year.

116 ding to baseline and longitudinal changes in eGFR and urinary albumin-to-creatinine ratio.

117 en or continued TDF, we estimated changes in eGFR and urine protein-to-creatinine ratio (UPCR) after

118 e ADC values were correlated with changes in eGFR, serum creatinine (SCr), systolic blood pressure (S

119 age renal disease (ESRD) or >=50% decline in eGFR (1.17, 1.05-1.30).

120 dent CKD (1.28, 1.18-1.39), >=30% decline in eGFR (1.23, 1.15-1.33), and end-stage renal disease (ESR

121 with allopurinol did not slow the decline in eGFR as compared with placebo.

122 , defined as a composite of a 50% decline in eGFR or incident ESKD.

123 Decline in eGFR slope before AKI episodes was steeper in people wit

124 The decline in eGFR was less for sacubitril/valsartan than for valsarta

125 t CKD, 5.8% (5.0-7.0%) with >=30% decline in eGFR, and 17.0% (13.1-20.4%) with ESRD or >=50% decline

126 (defined as a sustained profound decline in eGFR, chronic dialysis, or transplant).

127 posite progression outcome (>=40% decline in eGFR, with eGFR<60 ml/min per 1.73 m(2), or ESKD), and l

128 % (13.1-20.4%) with ESRD or >=50% decline in eGFR.

129 ase (CKD) - defined as confirmed decrease in eGFR <=60 ml/min/1.73 m2 over three months apart.

130 sformed PA, there was an average decrease in eGFR of 0.38 ml/min/1.73 m2 (95% CI: -0.75, -0.01; p = 0

131 The 12-month difference in eGFR between the HMPO(2) and HMP groups was not signific

132 imary analysis, we detected no difference in eGFR for the intervention and control groups 2 years aft

133 redicted a 5.68 ml/min/1.73 m(2) increase in eGFR (95% Confidence Interval (CI): 3.75, 7.61).

134 R group, there was a substantial increase in eGFR seen during follow-up with a mean gain of 11 mL/min

135 entrations were associated with increases in eGFR, but only when baseline levels (vs.

136 id not predict a more negative trajectory in eGFR slope.

137 Incident eGFR <60 ml/min per 1.73 m(2) was associated with a high

138 , 1.07-1.39), and increased risk of incident eGFR <60 ml/min/1.73 m(2) (hazard ratio:1.20, 95% CI: 1.

139 The main outcome was incident eGFR <45 ml/min per 1.73 m(2) at 12 months postnephrecto

140 of the association of PM(2.5) with incident eGFR <60 ml/min/1.73 m(2), 4.8% (4.2-5.8%) with incident

141 ant multivariable predictors of AKI included eGFR before imaging (OR: 0.99; 95% CI: 0.98, 0.995; P =

142 ) and validated (2015) a model incorporating eGFR using national data (n = 17,095) to predict WL mort

143 ly variable but in addition intra-individual eGFR trajectories also were frequently non-linear.

144 y DKD because of non-linear intra-individual eGFR trajectories.

145 Interindividual eGFR decline was highly variable but in addition intra-i

146 D), and linear mixed models for longitudinal eGFR measures.

147 dG were analyzed in relation to longitudinal eGFR (per log-unit increase in 8-OHdG, beta = 0.81, 95%

148 were considered in relation to longitudinal eGFR.

149 In demographically adjusted models, low eGFR and high ACR were associated with cancer incidence

150 hat failure was strongly associated with low eGFR, AKI, CKD, and glomerular deterioration, but not wi

151 tformin prescription among patients with low eGFR.

152 a=-17 ml/d per 10 ml/min per 1.73 m(2) lower eGFR; 95% CI, -21 to -12).

153 Although lower eGFR and higher plasma indoxyl sulfate correlated with l

154 g), diabetes (versus no diabetes), and lower eGFR (<60 versus >=60 ml/min/1.73m2).

155 ated strong agreement, particularly at lower eGFR values.

156 retic effects on body weight and BP at lower eGFR were maintained.

157 ts stopped RAS inhibition at higher or lower eGFR, across prespecified subgroups, after adjustment an

158 sex, race, and estimated blood volume, lower eGFR was associated with reduced 25(OH)D clearance (beta

159 d pressure, but PA was associated with lower eGFR over time.

160 Mean eGFR at 12 months was 50.5 mL/min per 1.73 m(2) (SD 19.3

161 Mean eGFR was 26.6 ml/min per 1.73 m(2); 45% of participants

162 A total of 26 patients (with a mean eGFR of 39 ml/min per 1.73 m(2)) completed both treatmen

163 During a median follow-up of 22 months, mean eGFR increased to 43 +/- 30 mL/min/1.73 m2.

164 The remaining 363 patients (mean eGFR, 31.7 ml per minute per 1.73 m(2); median urine alb

165 though proteinuria remained stable, the mean eGFR decline during part A was slower with clazakizumab

166 with a mean age of 57.7 years, and the mean eGFR is 44.9 ml/min/1.73m2.

167 The mean eGFR value after the 24-month follow-up was significantl

168 Median eGFR was 23 ml/min per 1.73 m(2).

169 Median age was 58 years (IQR, 52-65), median eGFR was 95 ml/min per 1.73 m(2) (IQR, 74-100) using the

170 a median creatinine of 1.2 mg/dl and median eGFR of 57 ml/min per 1.73 m(2) at 6 months.

171 ian age was 71 years, 54.7% were men, median eGFR was 51.3 mL/min/1.73 m(2)) and observed that the nu

172 e of 58 years and 41% were black; the median eGFR was 43 ml/min per 1.73 m(2).

173 y associated with increased BMI in both men [eGFR-adjusted beta 0.443 (0.163-0.724)] and women [0.594

174 The mean 12-month eGFR for AKI kidney recipients was lower, but difference

175 study of 87 adults, including 43 with normal eGFR (>=60 ml/min per 1.73 m(2)), 24 with nondialysis CK

176 5(OH)D clearance in participants with normal eGFR, but not in those with CKD or kidney failure (P for

177 /d, and 263 ml/d in participants with normal eGFR, CKD, and kidney failure, respectively (P=0.02).

178 Coronary microvascular dysfunction, but not eGFR, was independently associated with abnormal cardiac

179 In multivariable models, CFR, but not eGFR, was independently associated with cardiac mechanic

180 ed difference between predicted and observed eGFR from 17.6 (using original htTKVs) to 4.0 ml/min per

181 ies study, we quantified the associations of eGFR (based on creatinine and cystatin C) and ACR with c

182 y drug dosing strategies are on the basis of eGFR.

183 holds of a percentage or absolute decline of eGFR after each year of follow up.

184 to severe CKD, we observed steep declines of eGFR were associated with progressively increasing risks

185 dpoint either as a percentage of decrease of eGFR (e.g. >= 30%) or an absolute decline (e.g. >= 5 ml/

186 Incorporation of eGFR likely captures true GFR better than SCr, especiall

187 sion and all-cause mortality, independent of eGFR and albuminuria.

188 th >=500 mg/g of proteinuria irrespective of eGFR.

189 timated biomarker relationships with rate of eGFR change.

190 levels were associated with a lower rate of eGFR decline in models adjusted for age, gender, hyperte

191 R-2, and YKL-40 were associated with rate of eGFR decline.

192 Rises of eGFR or declines lower than the average decline were not

193 During part B, the slope of eGFR decline for patients who were switched from placebo

194 Slopes of eGFR have been associated with increased risks of death

195 ucted an epigenome-wide association study of eGFR among 567 HIV-positive and 117 HIV-negative male pa

196 hese findings support the potential value of eGFR slopes in clinical assessment of adults with CKD.

197 s composite, and the influence of therapy on eGFR slope.

198 ian age 72 years, 36% female) with new-onset eGFR <30 ml/min per 1.73 m(2), 1553 (15%) stopped RAS in

199 MRI in a patient with acute kidney injury or eGFR less than 30 mL/min per 1.73 m(2) should be balance

200 statistical differences were found in TKV or eGFR change.

201 Renal oxygenation, eGFR, and SCr improved after MT + PTRA.

202 ation, or a 40% decline from postnephrectomy eGFR).

203 sis using K-fold cross validation to predict eGFR loss of >= 3 ml/min/1.73m(2)/year showed that UPPod

204 fference +/-SD for observed versus predicted eGFR: 2.18 +/- 10.7 mL/min/1.73 m(2); p = 0.0475).

205 albuminuria were equally good at predicting eGFR loss.

206 Because htTKV poorly predicts eGFR decline for the 5%-10% of patients with atypical mo

207 d two functioning kidneys and a preoperative eGFR >=60 ml/min per 1.73 m(2).

208 5 years old, diabetes mellitus, preoperative eGFR, and nephrectomy type (partial/radical)-to fit logi

209 ndent population with a relatively preserved eGFR at baseline and at least 5 years of follow up.

210 At randomization, eGFR was 63+/-19 mL.min(-1).1.73 m(-)2.

211 seline estimated glomerular filtration rate (eGFR >90 mL/minute/1.73 m2).

212 first estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m2 after January 1, 2002.

213 eline (estimated glomerular filtration rate (eGFR) <= 60 mL/min/BSA) (n = 118), we collected clinical

214 s with estimated glomerular filtration rate (eGFR) 59 to 30 mL/min/1.73 m2 on two consecutive previou

215 rative estimated glomerular filtration rate (eGFR) and serum creatinine were noted.

216 sures, estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (ACR), wit

217 Estimated glomerular filtration rate (eGFR) based on serum creatinine (sCr) improves early aft

218 io and estimated glomerular filtration rate (eGFR) based on serum creatinine and cystatin C.

219 ied by estimated glomerular filtration rate (eGFR) before imaging (>=60 mL/min/1.73 m(2) or <60 mL/mi

220 th and estimated glomerular filtration rate (eGFR) decline over 3 years.

221 of the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease who are at

222 a mean estimated glomerular filtration rate (eGFR) of 13 +/- 11 mL/min/1.73 m2, and 82% had stage 3 a

223 00, an estimated glomerular filtration rate (eGFR) of 25 to less than 60 ml per minute per 1.73 m(2)

224 d with estimated glomerular filtration rate (eGFR) over time and a log-unit increase in baseline 8-OH

225 act on estimated glomerular filtration rate (eGFR) remains unclear.

226 Median estimated glomerular filtration rate (eGFR) was 43.7 ml/min/1.73 m(2) (interquartile range: 30

227 ed and estimated glomerular filtration rate (eGFR) was calculated.

228 ge and estimated glomerular filtration rate (eGFR) were identified.

229 MI and estimated glomerular filtration rate (eGFR) were used.

230 seline estimated glomerular filtration rate (eGFR) with the Chronic Kidney Disease Epidemiology Colla

231 t-TAVR estimated glomerular filtration rate (eGFR), and assess association of post-TAVR eGFR with mor

232 -CRP), estimated glomerular filtration rate (eGFR), and homeostasis model assessment of insulin resis

233 ssure, estimated glomerular filtration rate (eGFR), and proteinuria.

234 ilure, estimated glomerular filtration rate (eGFR), body-mass index, and region (post-hoc).

235 ion in estimated glomerular filtration rate (eGFR), end-stage renal disease, or death from renal caus

236 cluded estimated glomerular filtration rate (eGFR), proteinuria, and blood pressure.

237 -month estimated glomerular filtration rate (eGFR), respectively.

238 educed estimated glomerular filtration rate (eGFR).

239 ia and estimated glomerular filtration rate (eGFR).

240 seline estimated glomerular filtration rate (eGFR, p < 0.001).

241 th the estimated glomerular filtration rate (eGFR, rho = -0.309, p < 0.0001).

242 eline (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m(2) or albumin-to-creatine ratio

243 res of estimated glomerular filtration rate [eGFR] <90 mL/min/1.73 m2 >=90 days apart).

244 kidney function (glomerular filtration rate, eGFR) and overall survival at 2 years posttransplant.

245 ey function, measured by clinically relevant eGFR subgroups or by albuminuria, including patients wit

246 We also replicated previously reported eGFR-associated CpG sites including cg17944885 (P = 2.5

247 Poor outcomes in individuals with rising eGFR are potentially attributable to sarcopenia, hemodil

248 (1) longitudinally compare CysC-eGFR and sCr-eGFR, (2) assess their predictive value for early postop

249 In the prospective cohort, sCr-eGFR significantly improved early post-LVAD and subseque

250 CysC-eGFR but not sCr-eGFR predicted the primary end point: odds ratio per 5 m

251 %) were of white ethnicity, and mean (+/-SD) eGFR was 53.5 +/- 11.9 mL/min/1.73 m2.

252 monitoring seems safe, results in a similar eGFR, and personalizes immunosuppressive therapy by lowe

253 Lower baseline and longitudinal post-TAVR eGFR were associated with lower intermediate-term surviv

254 (eGFR), and assess association of post-TAVR eGFR with mortality.

255 In all 8 events, uCrCl was lower than eGFR (mean uCrCl vs. eGFR: 43 versus 112 ml/min/1.73m(2)

256 nd adjusted for ESKD risk factors other than eGFR (<median level: cause-specific hazard ratio [HR] 0.

257 The eGFR value nearest to each MRI examination was used.

258 The eGFR-adjusted multivariate analysis showed that relative

259 a sustained decrease of at least 40% in the eGFR from baseline, or death from renal causes.

260 ed CKD progression by a >=50% decline in the eGFR, initiation of maintenance dialysis, or kidney tran

261 sease (a composite of ESKD or halving of the eGFR), and mortality.

262 filtration (eGFR) as well as based on their eGFR at the time of transplant.

263 ) and at least 1 year of follow-up and three eGFR values.

264 were related to molecular AKI and CKD and to eGFR, not rejection activity, presumably because rejecti

265 nly urinary markers significantly related to eGFR slope were UPPod:CR (P < 0.01) and albuminuria (P <

266 g serum creatinine-based thresholds to using eGFR-based thresholds.

267 s, uCrCl was lower than eGFR (mean uCrCl vs. eGFR: 43 versus 112 ml/min/1.73m(2)).

268 Compared with the patients on waitlist eGFR >=60 mL/min/1.73 m, the adjusted subdistribution ha

269 Compared with the patients on waitlist eGFR >=60 mL/min/1.73m, the adjusted hazard ratio for mo

270 Primary end point was eGFR 2 years after transplantation.

271 antly greater effect on extracellular water, eGFR, plasma renin, and aldosterone.

272 tors for ESKD and/or death at 18 months were eGFR <15 ml/min per 1.73 m(2) at diagnosis (IRR 3.09 [95

273 We investigated whether eGFR only is safe in this setting.

274 efined as eGFR <60 ml/min per 1.73 m(2) with eGFR decline >=1 ml/min per 1.73 m(2) per year, or urine

275 ses of NaHCO(3) over 28 weeks in adults with eGFR 20-44 or 45-59 ml/min per 1.73 m(2) with urinary al

276 Frequency of AKI with eGFR greater than or equal to 60 mL/min/1.73 m(2) was 2.

277 [CI]: 0.52, 1.86; adjusted P = .95) and with eGFR less than 60 mL/min/1.73 m(2) was 5.6% (two of 36)

278 e evaluated baseline factors associated with eGFR <90 mL/min/1.73 m2 by logistic regression.

279 the adjusted model, factors associated with eGFR <90 mL/min/1.73 m2 included white race, older age,

280 nd LTV1, were all negatively associated with eGFR (cg06329547, P = 5.25 x 10-9; cg23281907, P = 1.37

281 ites that were significantly associated with eGFR (false discovery rate Q value < 0.05) among HIV-pos

282 we found no increased risks associated with eGFR improvement.

283 were jointly and nonlinearly associated with eGFR in black women.

284 ia at baseline, UPPod:CR was associated with eGFR loss rate (P = 0.003).

285 thalate metabolites were not associated with eGFR, proteinuria, or blood pressure, but PA was associa

286 the extent of cast formation correlated with eGFR value at LCCN diagnosis.

287 ression outcome (>=40% decline in eGFR, with eGFR<60 ml/min per 1.73 m(2), or ESKD), and linear mixed

288 .91 (CI, 2.4-3.5) in the patient groups with eGFR of 45-59, 30-44, and <30 mL/min/1.73 m, respectivel

289 1.04 (0.91-1.19) in the patient groups with eGFR of 45-59, 30-44, and <30 mL/min/1.73m, respectively

290 Men with eGFR of 30-44 ml/min per 1.73 m(2) received metformin pr

291 s or by albuminuria, including patients with eGFR as low as 20 ml/min/1.73 m(2).

292 We categorized 146,132 patients with eGFR data in 2016 or 2017 and examined nonmutually exclu

293 Seventeen patients with eGFR less than 30 mL/min/1.73 m(2) or undergoing dialysi

294 before the label change, Black patients with eGFR of 30-44 ml/min per 1.73 m(2) were prescribed metfo

295 m(2), 40 examinations (in 39 patients) with eGFR less than 15 mL/min/1.73 m(2), and 34 examinations

296 (2) and 183 examinations (157 patients) with eGFR less than 30 mL/min/1.73 m(2).

297 were 109 examinations (in 94 patients) with eGFR of 15-29 mL/min/1.73 m(2), 40 examinations (in 39 p

298 ncluded 299 examinations (242 patients) with eGFR of 30-44 mL/min/1.73 m(2) and 183 examinations (157

299 eposition that correlated significantly with eGFR and crescent formation.

300 In a subcohort with eGFR<60 ml/min per 1.73 m(2), we then used the kidney fa